title: Retroperitoneal fibrosis caused by pergolide in a patient with Parkinson's disease.
abstract: Retroperitoneal fibrosis (RPF) is an uncommon disorder that may cause ureteric obstruction with renal damage. Pergolide, a dopaminergic agonist used in the treatment of Parkinson's disease, has rarely been related to the development of RPF. We report on a 78-year-old woman with Parkinson's disease who presented with hydroureteronephrosis and developed RPF and serosal fibrosis during treatment with pergolide. Following discontinuation of pergolide therapy and placement of a double-J stent, her renal function improved. Inflammatory markers returned to normal limits within two months and the retroperitoneal fibrotic mass became smaller.
authors.affiliation: Department of Internal Medicine, Cerrahpasa School of Medicine, Istanbul University, Istanbul, Turkey. ahmetknower@softhome.net
authors.forename: A
authors.initials: A
authors.lastname: Bilici
authors.forename: B
authors.initials: B
authors.lastname: Karadag
authors.forename: A
authors.initials: A
authors.lastname: Doventas
authors.forename: D Suna
authors.initials: DS
authors.lastname: Erdincler
authors.forename: S
authors.initials: S
authors.lastname: Cetinkaya
authors.forename: G
authors.initials: G
authors.lastname: Ogut
authors.forename: V
authors.initials: V
authors.lastname: Tezcan
authors.forename: T
authors.initials: T
authors.lastname: Beger
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D010300:Parkinson Disease / Q000188:drug therapy*; D010479:Pergolide / Q000009:adverse effects* / Q000627:therapeutic use; D012185:Retroperitoneal Fibrosis / Q000139:chemically induced*
chemical_list: D000978:Antiparkinson Agents; D010479:Pergolide